Dear Dr. Phillips:

Please refer to your biologics license application (BLA) dated and received September 17, 2020, and your amendments, submitted under section 351(k) of the Public Health Service Act for BYOOVIZ (ranibizumab-nuna) injection, 0.5 mg (10 mg/mL) in a single-dose vial.

**Licensing**
We have approved your BLA for BYOOVIZ (ranibizumab-nuna) effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce, BYOOVIZ under your existing Department of Health and Human Services U.S. License No. 2046. BYOOVIZ is indicated for the treatment of Neovascular (wet) Age-related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), and Myopic Choroidal Neovascularization (mCNV).

**Manufacturing Locations**
Under the license you are approved to manufacture ranibizumab-nuna drug substance at [redacted]. The final formulated drug product will be manufactured and filled at [redacted] and packaged at [redacted]. The filled drug product will be labeled and marketed with the proprietary name, BYOOVIZ, and market it in 0.5 mg (10 mg/mL) single-dose vials.

**Dating Period**
The dating period for BYOOVIZ shall be 30 months from the date of manufacture when stored at 2°C - 8°C, protected from light. The date of manufacture shall be defined as the date of final sterile filtration of the formulated drug product. The dating period for your drug substance shall be [redacted] months from the date of manufacture when stored at [redacted].

We have approved the stability protocol in your license application for the purpose of extending the expiration dating period of your drug substance and drug product under 21 CFR 601.12.
FDA LOT RELEASE
You are not currently required to submit samples of future lots of BYOOVIZ to the Center for Drug Evaluation and Research (CDER) for release by the Director, CDER, under 21 CFR 610.2. We will continue to monitor compliance with 21 CFR 610.1, requiring completion of tests for conformity with standards applicable to each product prior to release of each lot.

Any changes in the manufacturing, testing, packaging, or labeling of BYOOVIZ, or in the manufacturing facilities, will require the submission of information to your BLA for our review and written approval, consistent with 21 CFR 601.12.

APPROVAL & LABELING
We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING
As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information). Information on submitting SPL files using eLIST may be found in the guidance for industry SPL Standard for Content of Labeling Technical Qs and As (October 2009). The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELING
Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications. For administrative purposes, designate this submission “Final Printed Carton and Container Labeling for approved BLA 761202.” Approval of this submission by FDA is not required before the labeling is used.

REQUIRED PEDIATRIC ASSESSMENTS
Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration

1 See http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm
2 We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database at https://www.fda.gov/RegulatoryInformation/Guidances/default.htm.

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
are required to contain an assessment of the safety and effectiveness of the product for
the claimed indications in pediatric patients unless this requirement is waived, deferred,
or inapplicable. At this time, we have determined that no pediatric studies will be
required under PREA for your BLA.

POSTMARKETING COMMITMENTS NOT SUBJECT TO THE REPORTING
REQUIREMENTS UNDER SECTION 506B
We remind you of your postmarketing commitments:

4108-1

Provide bioburden test method suitability data for in-process samples from at least one
additional lot of SB11 drug substance.

The timetable you submitted on July 13, 2021, states that you will conduct this study
and submit the Final Report results by December 31, 2021.

4108-2

Perform real-time drug product commercial container closure system leachate studies
using appropriate test methods to identify and quantify volatile organic compounds
(VOC), semi-VOC, non-VOC, and trace metals at regular intervals through the end of
shelf life. The study results will be updated annually in the BLA Annual Report. The
final results of this study and the toxicology risk evaluation for the levels of leachates
detected in the drug product will be provided in the final study report to the BLA.

The timetable you submitted on July 13, 2021, states that you will conduct this study
and submit the Final Report results by December 31, 2024.

Submit nonclinical and chemistry, manufacturing, and controls protocols and all
postmarketing final reports to this BLA. In addition, under 21 CFR 601.70 you should
include a status summary of each commitment in your annual progress report of
postmarketing studies to this BLA. The status summary should include expected
summary completion and final report submission dates, any changes in plans since the
last annual report, and, for clinical studies/trials, number of patients entered into each
study/trial. All submissions, including supplements, relating to these postmarketing
commitments should be prominently labeled “Postmarketing Commitment Protocol,”
“Postmarketing Commitment Final Report,” or “Postmarketing Commitment
Correspondence.”

PROMOTIONAL MATERIALS
You may request advisory comments on proposed introductory advertising and
promotional labeling. For information about submitting promotional materials, see the
final guidance for industry Providing Regulatory Submissions in Electronic and

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

Reference ID: 4858483
Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs.³

You must submit final promotional materials and Prescribing Information, accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS
You must submit adverse experience reports under the adverse experience reporting requirements for licensed biological products (21 CFR 600.80). Prominently identify all adverse experience reports as described in 21 CFR 600.80. You must submit distribution reports under the distribution reporting requirements for licensed biological products (21 CFR 600.81).

You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
5901-B Ammendale Road
Beltsville, MD 20705-1266

Biological product deviations, sent by courier or overnight mail, should be addressed to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Compliance Risk Management and Surveillance
10903 New Hampshire Avenue, Bldg. 51, Room 4207
Silver Spring, MD 20903

BsUFA II APPLICANT INTERVIEW
FDA has contracted with Eastern Research Group, Inc. (ERG) to conduct an independent interim and final assessment of the Program for Enhanced Review Transparency and Communication for Original 351(k) BLAs under BsUFA II (‘the Program’). The BsUFA II Commitment Letter states that these assessments will include

³ For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/media/128163/download.
⁴ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf
⁵ http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov
interviews with applicants following FDA action on applications reviewed in the Program. For this purpose, first-cycle actions include approvals, complete responses, and withdrawals after filing. The purpose of the interview is to better understand applicant experiences with the Program and its ability to improve transparency and communication during FDA review.

ERG will contact you to schedule a BsUFA II applicant interview and provide specifics about the interview process. Your responses during the interview will be confidential with respect to the FDA review team. ERG has signed a non-disclosure agreement and will not disclose any identifying information to anyone outside their project team. They will report only anonymized results and findings in the interim and final assessments. Members of the FDA review team will be interviewed by ERG separately. While your participation in the interview is voluntary, your feedback will be helpful to these assessments.

POST APPROVAL FEEDBACK MEETING
New biological products qualify for a post-approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, please call the Regulatory Project Manager for this application.

If you have any questions, call Lois Almoza, MS, Senior Regulatory Project Manager, at (240) 402-5146.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, MD
Director
Division of Ophthalmology
Office of Specialty Medicine
Center for Drug Evaluation and Research

ENCLOSURES:
- Content of Labeling
  - Prescribing Information
- Carton and Container Labeling
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

WILEY A CHAMBERS
09/17/2021 06:04:23 PM